Sandoz Champions Stability As It Returns To Growth In Q2
Investments In Biosimilars Will Spearhead Financial Goals
Executive Summary
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
You may also be interested in...
Gan & Lee Insulins Data Is Boon For Sandoz
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.
Sandoz Launches Pemetrexed In 11 European Countries
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
Sandoz To Close Barcelona Plant Under Antibiotics Manufacturing Revamp
Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”